Perceptions of genetic testing for cancer predisposition among Ashkenazi Jewish women

Community Genetics

Volumn 10, Issue 2, 2007, Pages 72-81

  Lewis, M Jane ^a,c   Peterson, Susan K ^b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NONE   (United States)

Author keywords

Ashkenazi; Focus groups; Genetic testing; Psychosocial distress

Indexed keywords

ADULT; AGED; ARTICLE; ATTITUDE TO HEALTH; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; COLORECTAL CANCER; EXPERIENCE; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; HUMAN; KNOWLEDGE; OVARY CANCER; PRIORITY JOURNAL; PRIVACY; RISK MANAGEMENT;

ADULT; AGED; AGED, 80 AND OVER; CONFIDENTIALITY; FEMALE; FOCUS GROUPS; GENETIC PREDISPOSITION TO DISEASE; GENETIC PRIVACY; GENETIC SCREENING; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; JEWS; MIDDLE AGED; NEOPLASMS; NEW JERSEY; SOCIOECONOMIC FACTORS;

EID: 33947518866     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099084     Document Type: Article

References (42)

1. Collins FS, Green ED, Guttmacher AE, Guyer MS, US National Human Genome Research Institute: A vision for the future of genomics research. Nature 2003;422:835-847.
2. Coughlin SS: The intersection of genetics, public health, and preventive medicine. Am J Prev Med 1999;16:89-90.
3. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 1996;14:188-190.
4. Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E, Shohat M, Weber BL, Beller U, Lahad A, Halle D: Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 1997;60:1059-1067.
5. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
6. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ: Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 1999;8:741-747.
7. King MC, Marks JH, Mandell JB, New York Breast Cancer Study Group: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-646.
8. Woodage T, King SM, Wacholder S, Hartge P, Struewing JP, McAdams M, Laken SJ, Tucker MA, Brody LC: The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet 1998;20:62-65.
9. Gryfe R, Di Nicola N, Lal G, Gallinger S, Redston M: Inherited colorectal polyposis and cancer risk of the APC I1307K polymorphism. Am J Hum Genet 1999;64:378-384.
10. Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E, Farber D, Greenwood CMT, Bonner JD, Nafa K, Walsh T, Marcus V, Tomsho L, Gebert J, Macrae FA, Gaff CL, Paillerets BBD, Gregersen PK, Weitzel JN, Gordon PH, MacNamara E, King MC, Hampel H, De La Chapelle A, Boyd J, Offit K, Rennert G, Chong G, Ellis NA: The founder mutation MSH2*1906G→C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 2002;71:1395-1412.
11. Rozen P, Naiman T, Strul H, Taussky P, Karminsky N, Shomrat R, Samuel Z, Yaron Y, Orr-Urtreger A: Clinical and screening implications of the I1307K adenomatous polyposis coli gene variant in Israeli Ashkenazi Jews with familial colorectal neoplasia. Evidence for a founder effect. Cancer 2002;94:2561-2568.
12. Guillem JG, Rapaport BS, Kirchhoff T, Kolachana P, Nafa K, Glogowski E, Finch R, Huang H, Foulkes WD, Markowitz A, Ellis NA, Offit K: A636P is associated with early-onset colon cancer in Ashkenazi Jews. J Am Coll Surg 2003;196:222-225.
13. Friedman LC, Webb JA, Richards CS, Lynch GR, Kaplan AL, Brunicardi FC, Plon SE: Psychological impact of receiving negative BRCA1 mutation test results in Ashkenazim. Genet Med 1999;1:74-79.
14. Phillips KA, Warner E, Meschino WS, Hunter J, Abdolell M, Glendon G, Andrulis IL, Goodwin PJ: Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2. Clin Genet 2000;57:376-383.
15. Schwartz MD, Benkendorf J, Lerman C, Isaacs C, Ryan-Robertson A, Johnson L: Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women. Cancer 2001;92:932-940.
16. Lehmann LS, Weeks JC, Klar N, Garber JE: A population-based study of Ashkenazi Jewish women's attitudes toward genetic discrimination and BRCA1/2 testing. Genet Med 2002;4:346-352.
17. Press NA, Yasui Y, Reynolds S, Durfy SJ, Burke W: Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am J Med Genet 2001;99:99-110.
18. Warner BJ, Curnow LJ, Polglase AL, Debinski HS: Factors influencing uptake of genetic testing for colorectal cancer risk in Australian Jewish population. J Genet Couns 2005;14:387-394.
19. Durfy SJ, Bowen DJ, McTiernan A, Sporleder J, Burke W: Attitudes and interest in genetic testing for breast and ovarian cancer susceptibility in diverse groups of women in western Washington. Cancer Epidemiol Biomarkers Prev 1999;8:369-375.
20. Krueger RA: A Practical Guide for Applied Research, ed 2. Thousand Oaks, Sage, 1994.
21. Kitzinger J: Qualitative research. Introducing focus groups. BMJ 1995;311:299-302.
22. Charatan FB: New Jersey passes genetic privacy bill. BMJ 1996;313:71.
23. Khoury MJ, McCabe LL, McCabe ERB: Population screening in the age of genomic medicine. N Engl J Med 2003;348:50-58.
24. Levin M: Screening Jews and genes: a consideration of the ethics of genetic screening within the Jewish community: challenges and responses. Genet Test 1999;3:207-213.
25. Lerman C, Croyle RT, Tercyak KP, Hamann H: Genetic testing: psychological aspects and implications. J Consult Clin Psychol 2002;70:784-797.
26. Escher M, Sappino AP: Primary care physicians' knowledge and attitudes towards genetic testing for breast-ovarian cancer predisposition. Ann Oncol 2000;11:1131-1135.
27. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, De La Chapelle A, Mecklin JP: Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000;118:829-834.
28. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-1622.
29. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL: Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1055-1062.
30. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA: Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-1325.
31. Wainberg S, Husted J: Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 2004;13:1989-1995.
32. Carnovale BV, Clanton MS: Genetic testing: issues related to privacy, employment, and health insurance. Cancer Pract 2002;10:102-104.
33. Lee SC, Bernhardt BA, Helzlsouer KJ: Utilization of BRCA1/2 genetic testing in the clinical setting: report from a single institution. Cancer 2002;94:1876-1885.
34. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD: Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79-87.
35. Hadley DW, Jenkins J, Dimond E, Nakahara K, Grogan L, Liewehr DJ, Steinberg SM, Kirsch I: Genetic counseling and testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med 2003;163:573-582.
36. Armstrong K, Weber B, Stopfer J, Calzone K, Putt M, Coyne J, Schwartz JS: Early use of clinical BRCA1/2 testing: associations with race and breast cancer risk. Am J Med Genet A 2003;117:154-160.
37. Freedman AN, Wideroff L, Olson L, Davis W, Klabunde C, Srinath KP, Reeve BB, Croyle RT, Ballard-Barbash R: US physicians' attitudes toward genetic testing for cancer susceptibility. Am J Med Genet A 2003;120:63-71.
38. Jacobellis J, Martin L, Engel J, VanEenwyk J, Bradley LA, Kassim S, et al: Genetic testing for breast and ovarian cancer susceptibility: evaluating direct-to-consumer marketing - Atlanta, Denver, Raleigh-Durham, and Seattle, 2003. MMWR 2004;53:603-606.
39. Lerman C, Narod S, Schulman K, Hughes C, Gomez-Caminero A, Bonney G, Gold K, Trock B, Main D, Lynch J, Fulmore C, Snyder C, Lemon SJ, Conway T, Tonin P, Lenoir G, Lynch H: BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996;275:1885-1892.
40. Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, Van der Meer CA, Van den Ouweland AM, Niermeijer MF: Psychological impact of receiving a BRCA1/BRCA2 test result. Am J Med Genet 2001;98:15-24.
41. Lodder L, Frets PG, Trijsburg RW, Klijn JGM, Seynaeve C, Tilanus MMA, Bartels CCM, Meijers-Heijboer EJ, Verhoog LC, Niermeijer MF: Attitudes and distress levels in women at risk to carry a BRCA1/BRCA2 gene mutation who decline genetic testing. Am J Med Genet A 2003;119:266-272.
42. Schwartz MD, Peshkin BN, Hughes C, Main D, Isaacs C, Lerman C: Impact of BRCA1/ BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol 2002;20:514-520.